Deal Snapshot: The companies had announced the deal back in February 2021, but citing its “strategic focus,” AbbVie told Caribou it was backing out.

The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.

The continuous glucose monitoring space is expanding fast enough to accommodate two big players. Both Dexcom and Abbott recorded double-digit sales growth during the last quarter.

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb looks back at ADA 2023 highlights and her interviews with diabetes company execs. Reed Miller discusses his Cardio Conversation with Volta Medical and Hannah Daniel discusses the FDA’s Clinical Decision Support Software final guidance.